Hydroxychloroquine-Induced Cardiomyopathy: Case Report, Pathophysiology, Diagnosis, and Treatment

Canadian Journal of Cardiology

Volumn 30, Issue 12, 2014, Pages 1706-1715

  Yogasundaram, Haran ^a   Putko, Brendan N ^a   Tien, Julia ^a   Paterson, D Ian ^a   Cujec, Bibiana ^a   Ringrose, Jennifer ^a   Oudit, Gavin Y ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; ANTIRHEUMATIC AGENT;

CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL STUDY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; HEART MUSCLE BIOPSY; HEART MUSCLE CONDUCTION DISTURBANCE; HEART VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; LYSOSOME STORAGE DISEASE; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SCREENING; TRANSTHORACIC ECHOCARDIOGRAPHY; ARTHRITIS, RHEUMATOID; BIOPSY; CARDIOMYOPATHIES; CASE REPORT; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; HEART MUSCLE; MIDDLE AGED; PATHOLOGY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOPSY; CARDIOMYOPATHIES; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYDROXYCHLOROQUINE; MIDDLE AGED; MYOCARDIUM;

EID: 84919781513     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.08.016     Document Type: Review

References (74)

1. Truong J., Yan A.T., Cramarossa G., Chan K.K. Chemotherapy-induced cardiotoxicity: detection, prevention, and management. Can J Cardiol 2014, 30:869-878.
2. Yeh E.T., Bickford C.L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. JAm Coll Cardiol 2009, 53:2231-2247.
3. Dec G.W., Fuster V. Idiopathic dilated cardiomyopathy. NEngl J Med 1994, 331:1564-1575.
4. Mackenzie A.H. Pharmacologic actions of 4-aminoquinoline compounds. Am J Med 1983, 75:5-10.
5. Slater A.F., Cerami A. Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites. Nature 1992, 355:167-169.
6. Saag K.G., Teng G.G., Patkar N.M., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784.
7. Ruiz-Irastorza G., Ramos-Casals M., Brito-Zeron P., Khamashta M.A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010, 69:20-28.
8. Tang C., Godfrey T., Stawell R., Nikpour M. Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Intern Med J 2012, 42:968-978.
9. Sullivan D.J., Gluzman I.Y., Russell D.G., Goldberg D.E. On the molecular mechanism of chloroquine's antimalarial action. Proc Natl Acad Sci U S A 1996, 93:11865-11870.
10. Katz S.J., Russell A.S. Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. Curr Opin Rheumatol 2011, 23:278-281.
11. Fox R.I. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993, 23:82-91.
12. Teixeira R.A., Borba E.F., Pedrosa A., et al. Evidence for cardiac safety and antiarrhythmic potential of chloroquine in systemic lupus erythematosus. Europace 2014, 16:887-892.
13. Hassan S.Z., Gheita T.A., Kenawy S.A., et al. Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: relationship to disease manifestations and activity. Int J Rheum Dis 2011, 14:325-331.
14. Roman M.J., Shanker B.A., Davis A., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. NEngl J Med 2003, 349:2399-2406.
15. Putko BN, Wen K, Thompson RB, etal. Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment [e-pub ahead of print]. Heart Fail Rev , accessed August 8, 2014. doi:10.1007/s10741-014-9452-9.
16. Marmor M.F., Carr R.E., Easterbrook M., et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a reportby the American Academy of Ophthalmology. Ophthalmology 2002, 109:1377-1382.
17. Michaelides M., Stover N.B., Francis P.J., Weleber R.G. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol 2011, 129:30-39.
18. Wolfe F., Marmor M.F. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res 2010, 62:775-784.
19. Whisnant J.P., Espinosa R.E., Kierland R.R., Lambert E.H. Chloroquine Neuromyopathy. Proc Staff Meet Mayo Clin 1963, 38:501-513.
20. Siddiqui A.K., Huberfeld S.I., Weidenheim K.M., Einberg K.R., Efferen L.S. Hydroxychloroquine-induced toxic myopathy causing respiratory failure. Chest 2007, 131:588-590.
21. Mastaglia F.L. Adverse effects of drugs on muscle. Drugs 1982, 24:304-321.
22. Stein M., Bell M.J., Ang L.C. Hydroxychloroquine neuromyotoxicity. JRheumatol 2000, 27:2927-2931.
23. Estes M.L., Ewing-Wilson D., Chou S.M., et al. Chloroquine neuromyotoxicity. Clinical and pathologic perspective. Am J Med 1987, 82:447-455.
24. Ratliff N.B., Estes M.L., Myles J.L., Shirey E.K., McMahon J.T. Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy. NEngl J Med 1987, 316:191-193.
25. Roos J.M., Aubry M.C., Edwards W.D. Chloroquine cardiotoxicity: clinicopathologic features in three patients and comparison with three patients with Fabry disease. Cardiovasc Pathol 2002, 11:277-283.
26. Naqvi T.Z., Luthringer D., Marchevsky A., et al. Chloroquine-induced cardiomyopathy-echocardiographic features. JAm Soc Echocardiogr 2005, 18:383-387.
27. Reffelmann T., Naami A., Spuentrup E., Kuhl H.P. Images in cardiovascular medicine. Contrast-enhanced magnetic resonance imaging of a patient with chloroquine-induced cardiomyopathy confirmed by endomyocardial biopsy. Circulation 2006, 114:e357-e358.
28. Pieroni M., Smaldone C., Camporeale A., et al. Images in cardiology. Chloroquine-induced transition from dilated to restrictive cardiomyopathy. JAm Coll Cardiol 2011, 57:515.
29. Tonnesmann E., Stroehmann I., Kandolf R., et al. Cardiomyopathy caused by long-term treatment with chloroquine: a rare disease, or a rare diagnosis?. JRheumatol 2012, 39:1099-1103.
30. Frustaci A., Morgante E., Antuzzi D., Russo M.A., Chimenti C. Inhibition of cardiomyocyte lysosomal activity in hydroxychloroquine cardiomyopathy. Int J Cardiol 2012, 157:117-119.
31. Arbustini E., Narula N., Dec G.W., et al. The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. JAm Coll Cardiol 2013, 62:2046-2072.
32. Tonnesmann E., Kandolf R., Lewalter T. Chloroquine cardiomyopathy - a review of the literature. Immunopharmacol Immunotoxicol 2013, 35:434-442.
33. Fitch C.D. Plasmodium falciparum in owl monkeys: drug resistance and chloroquine binding capacity. Science 1970, 169:289-290.
34. Silva J.C., Mariz H.A., Rocha L.F., et al. Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics 2013, 68:766-771.
35. Kahlenberg J.M., Kaplan M.J. The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus. Arthritis Res Ther 2011, 13:203.
36. Ducharme J., Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet 1996, 31:257-274.
37. Tett S.E. Clinical pharmacokinetics of slow-acting antirheumatic drugs. Clin Pharmacokinet 1993, 25:392-407.
38. Sumpter M.D., Tatro L.S., Stoecker W.V., Rader R.K. Evidence for risk of cardiomyopathy with hydroxychloroquine. Lupus 2012, 21:1594-1596.
39. Costedoat-Chalumeau N., Hulot J.S., Amoura Z., et al. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology 2007, 46:808-810.
40. Edwards A.C., Meredith T.J., Sowton E. Complete heart-block due to chronic chloroquine toxicity managed with permanent pacemaker. Br Med J 1978, 1:1109-1110.
41. Vereckei A., Fazakas A., Balo T., et al. Chloroquine cardiotoxicity mimicking connective tissue disease heart involvement. Immunopharmacol Immunotoxicol 2013, 35:304-306.
42. Yap Y.G., Camm A.J. Drug-induced QT prolongation and torsades de pointes. Heart 2003, 89:1363-1372.
43. Stas P., Faes D., Noyens P. Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine. Int J Cardiol 2008, 127:e80-e82.
44. Seferovic P.M., Ristic A.D., Maksimovic R., et al. Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases. Rheumatology 2006, 45(suppl 4):iv39-42.
45. Comin-Colet J., Sanchez-Corral M.A., Alegre-Sancho J.J., et al. Complete heart block in an adult with systemic lupus erythematosus and recent onset of hydroxychloroquine therapy. Lupus 2001, 10:59-62.
46. Martinezcosta X., Ordi J., Barbera J., et al. High-grade atrioventricular heart-block in 2 adults with systemic lupus-erythematosus. JRheumatol 1991, 18:1926-1928.
47. Fonseca E., Crespo M., Sobrino J.A. Complete heart block in an adult with systemic lupus erythematosus. Lupus 1994, 3:129-131.
48. Olken D., Volastro P., Finck D., Tulgan H., Mazur P. Heart block in systemic lupus erythematosus complicated by pacemaker "exit block". Arthritis Rheum 1991, 34:121-123.
49. Wozniacka A., Cygankiewicz I., Chudzik M., Sysa-Jedrzejowska A., Wranicz J.K. The cardiac safety of chloroquine phosphate treatment in patients with systemic lupus erythematosus: the influence on arrhythmia, heart rate variability and repolarization parameters. Lupus 2006, 15:521-525.
50. Acharya D., Robertson P., Kay G.N., et al. Arrhythmias in Fabry cardiomyopathy. Clin Cardiol 2012, 35:738-740.
51. Ferrans V.J., Hall R.J., McAllister H.A. Images in cardiovascular medicine. Chloroquine-induced cardiomyopathy. Circulation 1993, 88:785-786.
52. Nishino I., Fu J., Tanji K., et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 2000, 406:906-910.
53. Ben-Zvi I., Kivity S., Langevitz P., Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 2012, 42:145-153.
54. Lee J.H., Chung W.B., Kang J.H., et al. Acase of chloroquine-induced cardiomyopathy that presented as sick sinus syndrome. Korean Circ J 2010, 40:604-608.
55. Perry C.N., Kyoi S., Hariharan N., et al. Novel methods for measuring cardiac autophagy invivo. Methods Enzymol 2009, 453:325-342.
56. Daniels B.H., McComb R.D., Mobley B.C., et al. LC3 and p62 as diagnostic markers of drug-induced autophagic vacuolar cardiomyopathy: a study of 3 cases. Am J Surg Pathol 2013, 37:1014-1021.
57. Gerard J.M., Stoupel N., Collier A., Flament-Durand J. Morphologic study of a neuromyopathy caused by prolonged chloroquine treatment. Eur Neurol 1973, 9:363-379.
58. Soong T.R., Barouch L.A., Champion H.C., Wigley F.M., Halushka M.K. New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy-a report of 2 cases. Hum Pathol 2007, 38:1858-1863.
59. Nandagudi A., Jury E.C., Alonzi D., et al. Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry's disease. Lupus 2013, 22:1070-1076.
60. Pieroni M., Bellocci F., Crea F. Letter by Pieroni etal regarding article, "Contrast-enhanced magnetic resonance imaging of a patient with chloroquine-induced cardiomyopathy confirmed by endomyocardial biopsy". Circulation 2007, 115:e67. [author reply: e68].
61. Goenka A.H., Flamm S.D. Cardiac magnetic resonance imaging for the investigation of cardiovascular disorders. Part 1: current applications. Tex Heart Inst J 2014, 41:7-20.
62. Thompson R.B., Chow K., Khan A., et al. T(1) mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging 2013, 6:637-645.
63. Yoshida A., Ishibashi-Ueda H., Yamada N., et al. Direct comparison of the diagnostic capability of cardiac magnetic resonance and endomyocardial biopsy in patients with heart failure. Eur J Heart Fail 2013, 15:166-175.
64. Elliott P., Arbustini E. The role of endomyocardial biopsy in the management of cardiovascular disease: a commentary on joint AHA/ACC/ESC guidelines. Heart 2009, 95:759-760.
65. Yilmaz A., Kindermann I., Kindermann M., et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation 2010, 122:900-909.
66. Leone O., Veinot J.P., Angelini A., et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol 2012, 21:245-274.
67. Cooper L.T., Baughman K.L., Feldman A.M., et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 2007, 116:2216-2233.
68. Casado E., Gratacos J., Tolosa C., et al. Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis 2006, 65:385-390.
69. Singh J.A., Furst D.E., Bharat A., et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64:625-639.
70. Guidelines for referral and management of systemic lupus erythematosus in adults American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum 1999, 42:1785-1796.
71. Scott D.L., Wolfe F., Huizinga T.W. Rheumatoid arthritis. Lancet 2010, 376:1094-1108.
72. White N.J. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 2007, 7:549-558.
73. Saussine A., Loriot M.A., Picard C., et al. Chloroquine cardiotoxicity in long-term lupus therapy in two patients [in French]. Ann Dermatol Venereol 2009, 136:530-535.
74. Figueredo V.M. Chemical cardiomyopathies: the negative effects of medications and nonprescribed drugs on the heart. Am J Med 2011, 124:480-488.